1305 related articles for article (PubMed ID: 28736340)
1. TFOS DEWS II pathophysiology report.
Bron AJ; de Paiva CS; Chauhan SK; Bonini S; Gabison EE; Jain S; Knop E; Markoulli M; Ogawa Y; Perez V; Uchino Y; Yokoi N; Zoukhri D; Sullivan DA
Ocul Surf; 2017 Jul; 15(3):438-510. PubMed ID: 28736340
[TBL] [Abstract][Full Text] [Related]
2. [A new approach for better comprehension of diseases of the ocular surface].
Baudouin C
J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
[TBL] [Abstract][Full Text] [Related]
3. TFOS DEWS II Tear Film Report.
Willcox MDP; Argüeso P; Georgiev GA; Holopainen JM; Laurie GW; Millar TJ; Papas EB; Rolland JP; Schmidt TA; Stahl U; Suarez T; Subbaraman LN; Uçakhan OÖ; Jones L
Ocul Surf; 2017 Jul; 15(3):366-403. PubMed ID: 28736338
[TBL] [Abstract][Full Text] [Related]
4. TFOS DEWS II Definition and Classification Report.
Craig JP; Nichols KK; Akpek EK; Caffery B; Dua HS; Joo CK; Liu Z; Nelson JD; Nichols JJ; Tsubota K; Stapleton F
Ocul Surf; 2017 Jul; 15(3):276-283. PubMed ID: 28736335
[TBL] [Abstract][Full Text] [Related]
5. TFOS DEWS II Diagnostic Methodology report.
Wolffsohn JS; Arita R; Chalmers R; Djalilian A; Dogru M; Dumbleton K; Gupta PK; Karpecki P; Lazreg S; Pult H; Sullivan BD; Tomlinson A; Tong L; Villani E; Yoon KC; Jones L; Craig JP
Ocul Surf; 2017 Jul; 15(3):539-574. PubMed ID: 28736342
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
Schneider E; Paulsen F; Jacobi C
Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
[TBL] [Abstract][Full Text] [Related]
7. Surgery of the conjunctiva.
Yokoi N; Inatomi T; Kinoshita S
Dev Ophthalmol; 2008; 41():138-158. PubMed ID: 18453766
[TBL] [Abstract][Full Text] [Related]
8. DRY EYE DISEASE. A REVIEW.
Zemanová M
Cesk Slov Oftalmol; 2021; 77(3):107–119. PubMed ID: 34107689
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival Tear Layer Temperature, Evaporation, Hyperosmolarity, Inflammation, Hyperemia, Tissue Damage, and Symptoms: A Review of an Amplifying Cascade.
McMonnies CW
Curr Eye Res; 2017 Dec; 42(12):1574-1584. PubMed ID: 29111837
[TBL] [Abstract][Full Text] [Related]
10. Ageing and the natural history of dry eye disease: A prospective registry-based cross-sectional study.
Wang MTM; Muntz A; Lim J; Kim JS; Lacerda L; Arora A; Craig JP
Ocul Surf; 2020 Oct; 18(4):736-741. PubMed ID: 32758530
[TBL] [Abstract][Full Text] [Related]
11. [Novel current and future therapy options for treatment of dry eye disease].
Messmer EM
Ophthalmologe; 2018 Feb; 115(2):100-106. PubMed ID: 29134276
[TBL] [Abstract][Full Text] [Related]
12. Report of the Inaugural Meeting of the TFOS i(2) = initiating innovation Series: Targeting the Unmet Need for Dry Eye Treatment.
Chao W; Belmonte C; Benitez Del Castillo JM; Bron AJ; Dua HS; Nichols KK; Novack GD; Schrader S; Willcox MD; Wolffsohn JS; Sullivan DA
Ocul Surf; 2016 Apr; 14(2):264-316. PubMed ID: 26774910
[TBL] [Abstract][Full Text] [Related]
13. Rethinking dry eye disease: a perspective on clinical implications.
Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
[TBL] [Abstract][Full Text] [Related]
14. Impact of blinking on ocular surface and tear film parameters.
Wang MTM; Tien L; Han A; Lee JM; Kim D; Markoulli M; Craig JP
Ocul Surf; 2018 Oct; 16(4):424-429. PubMed ID: 29883739
[TBL] [Abstract][Full Text] [Related]
15. Systemic risk factors of dry eye disease subtypes: A New Zealand cross-sectional study.
Wang MTM; Vidal-Rohr M; Muntz A; Diprose WK; Ormonde SE; Wolffsohn JS; Craig JP
Ocul Surf; 2020 Jul; 18(3):374-380. PubMed ID: 32311433
[TBL] [Abstract][Full Text] [Related]
16. A mass and solute balance model for tear volume and osmolarity in the normal and the dry eye.
Gaffney EA; Tiffany JM; Yokoi N; Bron AJ
Prog Retin Eye Res; 2010 Jan; 29(1):59-78. PubMed ID: 19944776
[TBL] [Abstract][Full Text] [Related]
17. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial.
Craig JP; Muntz A; Wang MTM; Luensmann D; Tan J; Trave Huarte S; Xue AL; Jones L; Willcox MDP; Wolffsohn JS
Ocul Surf; 2021 Apr; 20():62-69. PubMed ID: 33401019
[TBL] [Abstract][Full Text] [Related]
18. An examination of the relationship between ocular surface tear osmolarity compartments and epitheliopathy.
McMonnies CW
Ocul Surf; 2015 Apr; 13(2):110-7. PubMed ID: 25881995
[TBL] [Abstract][Full Text] [Related]
19. Effects of tear hyperosmolarity on conjunctival cells in mild to moderate dry eye.
Julio G; Lluch S; Pujol P; Merindano MD
Ophthalmic Physiol Opt; 2012 Jul; 32(4):317-23. PubMed ID: 22620852
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
